Delving into the Latest Updates on ImmunoVec, Inc. with Synapse

Overview

Tags

Congenital Disorders

Other Diseases

Immune System Diseases

Gene editing

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Gene editing	1
Gene therapy	1

Top 5 Target	Count

CYBB(Cytochrome b-245 heavy chain)	1
CD34(Hematopoietic progenitor cell antigen CD34)	1

AbstractHIV-1 Vpr promotes efficient spread of HIV-1 from macrophages to T cells by transcriptionally downmodulating restriction factors that target HIV-1 Envelope protein (Env). Here we find that Vpr induces broad transcriptomic changes by targeting PU.1, a transcription factor necessary for expression of host innate immune response genes, including those that target Env. Consistent with this, we find silencing PU.1 in infected macrophages lacking Vpr rescues Env. Vpr downmodulates PU.1 through a proteasomal degradation pathway that depends on physical interactions with PU.1 and DCAF1, a component of the Cul4A E3 ubiquitin ligase. The capacity for Vpr to target PU.1 is highly conserved across primate lentiviruses. In addition to impacting infected cells, we find that Vpr suppresses expression of innate immune response genes in uninfected bystander cells, and that virion-associated Vpr can degrade PU.1. Together, we demonstrate Vpr counteracts PU.1 in macrophages to blunt antiviral immune responses and promote viral spread.

100 Deals associated with ImmunoVec, Inc.

Login to view more data

100 Translational Medicine associated with ImmunoVec, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MyeloVec ( CYBB )	Granulomatous Disease, Chronic More	Preclinical
Wiskott-Aldrich Syndrome therapy (ImmunoVec) ( CD34 )	Wiskott-Aldrich Syndrome More	Discovery